Telix Pharmaceuticals to acquire and merge with BlackRock-backed ITM for up to $2.35bn
Telix will pay $1.65 billion in cash upfront for 100 percent of ITM's shares, plus up to $700 million in contingency payments. The post Telix Pharmaceuticals to acquire and merge with BlackRock-backed ITM for up to $2.35bn appeared first on PE Hub .
We haven't written up this one. PE Hub has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.